Transcept announces Intermezzo tablet preliminary data for insomnia

Transcept Pharmaceuticals, Inc. (Nasdaq: TSPT) today announced its preliminary analysis of data from the recently completed Intermezzo® 3.5 mg (zolpidem tartrate sublingual tablet) highway driving study.

Transcept is developing Intermezzo® for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep. In the Intermezzo® New Drug Application (NDA), Transcept proposed to the U.S. Food and Drug Administration (FDA) that patients have at least four hours remaining in bed after dosing Intermezzo® in the middle of the night.